Art­bio emerges with $23M to make ra­di­oli­gand ther­a­pies for prostate can­cer, with field still in 'ear­ly days'

An­oth­er start­up is en­ter­ing the ra­dio­phar­ma mar­ket, backed by F-Prime Cap­i­tal and Omega Funds, with an ex­pe­ri­enced team from No­var­tis and Bay­er.

Art­bio is launch­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER